ESMO 2026 has ended. This guide stays up as the record of who was there. Next: ESMO 2027, Sep 17–21, 2027 in Barcelona
AstraZeneca at ESMO 2026
Oct 23–27, 2026 Madrid, Spain ~37k attendees Website
AstraZeneca takes part in 9 sessions at ESMO 2026 in Madrid, and exhibits at Booth 8066. Its program focuses on treatment advances in lung, breast, and gastroesophageal cancers, including biomarkers and combinations. It also covers antibody-drug conjugate care and the role of nurses in advanced breast cancer.
| Organization | ESMO 2026 Attendance |
|---|---|
AstraZeneca Cambridge, United Kingdom | |
Global pharmaceutical company with a large oncology portfolio including osimertinib, durvalumab, olaparib and trastuzumab deruxtecan. | Booth Exhibiting at Booth 8066 Poster Fri Oct 23 13:00–15:00 Talk Fri Oct 23 13:30 Poster Fri Oct 23 15:15–16:00 Poster Fri Oct 23 15:15–16:00 Satellite Fri Oct 23 18:15–19:45 AstraZeneca - Advancing excellence in lung cancer: New biomarkers, novel combinations, and changing standards of care Lung & thoracic cancersBiomarkers & precision oncology Satellite Sat Oct 24 13:00–14:30 Satellite Sun Oct 25 10:15–11:45 AstraZeneca - On the frontlines: Optimizing ADC patient care in lung cancer Lung & thoracic cancersNursing & supportive care Satellite Sun Oct 25 12:00–13:00 Daiichi Sankyo | AstraZeneca - Piecing together the ADC patient journey: The vital role of nurses in advanced breast cancer care Breast cancerNursing & supportive care Satellite Mon Oct 26 13:00–14:30 AstraZeneca - Advancing clinical practice and patient care in gastroesophageal cancer Gastrointestinal cancers |
Find decision makers at AstraZeneca
Tell us what you sell and we’ll find the people at AstraZeneca most likely to buy it.
- Who to contact
- Their contact info
- What to say
- Free, no sign-up
Not affiliated with or endorsed by the European Society for Medical Oncology. Submit a correction